ALK expands Catalent partnership: what it means for Catalent stock

Published on 10/01/2026 at 15:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ALK will invest DKK 500 million over three years in Catalent capacity. For Catalent stock, this means private ownership since December 18, 2024.

CTLT, US1488061029, Illustration mit AI erstellt.

Catalent (ISIN US1488061029) is expanding its manufacturing role with ALK, which will invest DKK 500 million over three years in additional Catalent capacity, according to BioSpace on September 30, 2026. For Catalent stock, the key issue is that the company is privately owned rather than publicly traded.

Capacity reaches 1.1 billion tablets

The expanded agreement gives ALK long-term access to Catalent's fast-dissolving Zydis tablet technology and prioritizes a 40.00 percent capacity increase to 1.1 billion tablets annually from the early 2030s. The increase equals 300 million additional tablets, creating a measurable operating link between Catalent's manufacturing network and ALK's allergy-treatment portfolio.

ALK said the capacity will support its sublingual immunotherapy tablets, including potential products for peanut and tree-nut allergies. The agreement is therefore more than a routine supply renewal: it adds a defined volume commitment and a multi-year investment program, while ALK said its 2026 financial guidance remains unchanged, according to BioSpace.

Debt and ownership define the outlook

Catalent's financing structure is another important reference point. Goodwin reported on September 1, 2026 that the company refinanced USD 4.7 billion of debt through a USD 4.1 billion equivalent seven-year term loan and a USD 600 million revolving credit facility. The structure gives the private business financing capacity, but it also places leverage at the center of its investor-relevant profile.

Historical scale provides context rather than a current public-company earnings picture. Catalent generated USD 4.381 billion of revenue in the fiscal year ended June 2024, while its Biologics segment generated USD 1.952 billion, according to the company profile published by Troy Technical in September 2026.

Private ownership changes Catalent stock

Troy Technical states that Novo Holdings completed its USD 16.5 billion acquisition of Catalent on December 18, 2024, ending the company's NYSE listing. The September 30 partnership is therefore best read as an operating development for a private CDMO, not as a conventional listed-stock catalyst.